Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.36 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL919725 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL146832 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL320155 | 0.98 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL919727 | 0.98 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL311871 | 0.98 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL8848963 | 0.88 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| Trifluoroacetic Acid SCHEMBL28911781 | 0.86 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5CA1 | |
| Trifluoroacetic Acid SCHEMBL28911780 | 0.86 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL28062530 | 0.85 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL1825341 | 0.84 | NOS1 (0.44) | NOS1NOS3NOS2SLC7A5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110269858-B | Twin medicine for treating ischemic stroke and preparation method thereof | 贵州医科大学 | 2021-07-09 | — | — | CN | claimed |
| CN-110269858-A | It is a kind of to treat twin medicine of cerebral arterial thrombosis and preparation method thereof | 贵州医科大学 | 2019-09-24 | — | — | CN | claimed |
| CN-122070146-A | Antibody coupling medicine, preparation method and application thereof | 杭州爱科瑞思生物医药有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709726-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4649081-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250250284-A1 | MACROCYCLE COMPOUNDS USEFUL AS KRAS INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-5273982-A | An amidinoaryleneamidoalkylpiperazinyleneacetic acid | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5162500-A | POSTSTATIN AND RELATED COMPOUNDS OR SALTS THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | disclosed |
| EP-0445796-A2 | Derivatives of acetic acid | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-11 | — | — | EP | disclosed |
| EP-0423358-A1 | POSTOSTATIN AND RELATED COMPOUND THEREOF, OR THEIR SALTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0067425-B1 | POSSIBLY PROTECTED PEPTIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1985-09-18 | — | — | EP | disclosed |
| EP-0067425-A1 | Possibly protected peptides, process for their preparation and pharmaceutical agents containing them | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1982-12-22 | — | — | EP | disclosed |
| US-4237046-A | VASODILATION | BOARD OF REGENTS THE, THE UNIVERSITY OF TEXAS SYSTEM | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | CA2 2775/4885DPP4 279/4885NOS1 454/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | CA2 1224/4885DPP4 139/4885NOS1 1820/4885 |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | CA2 1159/4885DPP4 4213/4885NOS1 4212/4885 |
| US-20250250284-A1 | MACROCYCLE COMPOUNDS USEFUL AS KRAS INHIBITORS | KRAS, NRAS, HRAS | CA2 1234/4885DPP4 4089/4885NOS1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.